*In adults with proteinuric CKD (with or without T2D),
FORXIGA^® reduced the risk of composite of ≥50% sustained decline in eGFR, ESKD,^¶ or renal or CV death, vs placebo (P<0.0001), both + SoC.^1,2
†In adults with HFrEF^# and HFpEF** (with or without T2D),
FORXIGA^® reduced the risk of composite of CV death or worsening of HF^§ vs placebo (P<0.0001 and P<0.001), both + SoC, respectively.^1,3,4
Dapagliflozin improves glycaemic control in patients with type 2 diabetes mellitus and provides cardio-renal benefits. The cardio-renal benefits of dapagliflozin are not solely dependent on the blood glucose-lowering effect and not limited to patients with diabetes.^{1 ¶}ESKD defined as the need for maintenance dialysis for at least 28 days, renal transplantation or sustained eGFR <15 mL/min/1.73 m² for at least 28 days;^{2 #}HFrEF defined as NYHA class II-IV HF and ejection fraction of ≤40;³ **HFpEF defined as NYHA class II-IV HF and ejection fraction of >40%;^{4 §}In DAPA-HF, worsening HF was defined as either an unplanned hospitalisation or an urgent visit resulting in intravenous therapy for HF; in DELIVER worsening HF was defined as either an unplanned hHF or an urgent visit for HF.^3,4

CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association; SoC, standard of care; T2D, type 2 diabetes.

References: 1. FORXIGA^® Approved Product Information. 2. Heerspink HJL et al. N Engl J Med. 2020;383(15):1436–1446. 3. McMurray JJV et al. N Engl J Med. 2019;381(21):1995–2008. 4. Solomon SD et al. N Engl J Med. 2022;387(12):1089–1098.

FORXIGA^® helps patients feel better^1–3

vs placebo (both + SoC) as measured by KCCQ^{^} in patients with HFrEF* and HFpEF^#

*HFrEF defined as NYHA class II-IV HF and ejection fraction of ≤40%;^{4 #}HFpEF defined as NYHA class II-IV and ejection fraction of >40%;^{5 ^}As measured by KCCQ scores (TSS, CSS, PLS, and OSS). The KCCQ is a 23-item, self-administered disease-specific instrument that quantifies symptoms (frequency, severity, and recent change), physical function, quality of life, and social function over the previous 2 weeks. In the KCCQ, the total symptom score (TSS) quantifies the symptom frequency and severity, KCCQ Physical Limitation Score (PLS) evaluates the physical function, KCCQ clinical summary score (CSS) includes the symptoms and physical function domains, and KCCQ overall summary score (OSS) summarises all key domains (TSS, physical function, quality of life, and social function). For each domain, the validity, reproducibility, responsiveness, and interpretability have been independently established. Scores are transformed to a range of 0 to 100, in which higher scores reflect better health status;^{2,3 †}In DAPA-HF, FORXIGA^® improved mean KCCQ-TSS, -CSS, and -OSS at 8 months (2.8, 2.5, and 2.3 points higher respectively vs placebo; nominal P<0.0001 for all) and in DELIVER, FORXIGA^® improved KCCQ-TSS, -PLS, -CSS, and -OSS at 8 months (2.4, 1.9, 2.3, and 2.1 points higher respectively vs placebo; nominal P<0.001 for all).^2,3

With FORXIGA^®, symptom improvement is more common, 
and deterioration is less common^1–3

vs placebo (both + SoC) as measured by KCCQ-TSS in patients with HFrEF* and HFpEF^#

Adapted from FORXIGA^® Approved product Information and Kosiborod et al, 2023.^1,3
*HFrEF defined as NYHA class II-IV HF and ejection fraction of ≤40%;^{4 #}HFpEF defined as NYHA class II-IV and ejection fraction of >40%;^{5 †}Taking account of death.¹

KCQQ study procedures and clinical outcomes^2,3

*HFrEF defined as NYHA class II-IV HF and ejection fraction of ≤40%;^{4 #}HFpEF defined as NYHA class II-IV HF and ejection fraction of >40%.⁵

CI, confidence interval; CSS, clinical summary score; CV, cardiovascular; DAPA-HF, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; DELIVER, Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire; OSS, overall summary score; PLS, physical limitation score; SoC, standard of care; TSS, total symptom score.

References: 1. FORXIGA^® Approved Product Information. 2. Kosiborod MN et al. Circulation. 2020;141:90–99. 3. Kosiborod MN et al. J Am Coll Cardiol. 2023;81(5):460–473. 4. McMurray JJV et al. N Engl J Med. 2019; 381(21):1995–2008. 5. Solomon SD et al. N Engl J Med. 2022;387:1089–1098.